Default Category
-
Principles of World-Class Execution: Winning in China
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4492BC-EFor multinational companies in China, the rapid evolution of markets and competition overwhelmingly demands an exacting focus on world-class execution. This chapter highlights the principles that should guide the efforts MNCs make as they ratchet up their ability to execute in China. This chapter is excerpted from "Operation China: From Strategy to Execution."Starting at €8.20
-
The Next Advantage for Manufacturing: Winning in China
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4495BC-EAs competition intensifies in China's new markets, pressures will mount on companies to improve their execution in every aspect of manufacturing. This chapter looks at how some companies have successfully tailored operations to the local realities of China. This chapter is excerpted from "Operation China: From Strategy to Execution."Starting at €8.20
-
Talent Holds the Key: Winning in China
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4498BC-EInside multinational companies that are playing to win in China, there is growing recognition that having a balance of global and local staff for important positions is effective for achieving the kind of creative insights needed to make fast, competitive judgments. This chapter is excerpted from "Operation China: From Strategy to Execution."Starting at €8.20
-
Becton Dickinson: Global Health Strategy
Kramer, Mark R.; Mehta, SarahCase HBS-718406-EStrategyBecton, Dickinson and Company (BD) was a medical technology firm headquartered in Franklin Lakes, New Jersey, with 43,000 employees and 2016 revenues of $12.5 billion. For several years, the company had pursued development of products that created shared value, defined as those that both generated profits and created positive social impact. One of the primary ways the company advanced such products was through establishing and maintaining public-...Starting at €8.20
-
Nestle's Creating Shared Value Strategy, Teaching Note
Kramer, Mark R.Teaching Note HBS-719460-EStrategyTeaching note for case 716422.Starting at €0.00
-
Changing Rules for Business Success: The Rising Bar for Execution in China
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4491BC-EThe business landscape in China has changed drastically within the last few years, and it continues to evolve at a rapid pace. This chapter shows how this changing landscape requires multinational companies operating here to urgently apply more managerial attention to execution. This chapter is excerpted from "Operation China: From Strategy to Execution."Starting at €8.20
-
Learning to Win in China's Many Markets
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4493BC-EToday and tomorrow, marketers in China must be able to monitor changes in their product areas and adapt to them more quickly than in most markets around the world, against fierce competition, and in an atmosphere of flux and uncertainty. The best of them will proactively shape emerging markets and customer segments, leveraging marketing capabilities by learning and adapting quickly. This chapter is excerpted from "Operation China: From Strategy ...Starting at €8.20
-
Win in China-or Lose Everywhere
Hexter, Jimmy; Woetzel, JonathanBook Chapter HBS-4501BC-EMultinational companies are bringing global standards and practices to China and adapting them to the tough realities of local markets. This chapter looks at how companies might use the adaptations forged here to succeed in other emerging markets, and in developed ones. This chapter is excerpted from "Operation China: From Strategy to Execution."Starting at €8.20
-
Social Business at Novartis: Arogya Parivar, Teaching Note
Kramer, Mark R.; Porter, Michael E.Teaching Note HBS-719426-EStrategyTeaching note for case 715411.Starting at €0.00
-
Social Business at Novartis: Arogya Parivar
Porter, Michael E.; Kramer, Mark R.; Lane, DavidCase HBS-715411-EStrategyLate in 2013, Novartis CEO Joseph Jimenez was considering how and whether to deepen the company's investment in Arogya Parivar, its profitable program that sold Novartis medicines in rural India, while expanding access to medicine and health information to millions of Indian villagers.Starting at €8.20